Equine gastric disease treatment still hinges on diagnosis, management

A December 3, 2025 educational item from The Horse on treatment approaches for equine gastric disease doesn’t announce a breakthrough, but it does crystallize where the field stands: accurate diagnosis first, pharmacologic treatment second, and management change throughout. That framing aligns closely with current review literature on equine gastric ulcer syndrome, which continues to separate equine squamous gastric disease, or ESGD, from equine glandular gastric disease, or EGGD, because the two conditions differ in pathophysiology, treatment response, and relapse patterns. (thehorse.com)

That distinction matters because EGUS remains common in domesticated and performance horses, and because treatment success is uneven across disease types. A 2022 invited review in The Veterinary Journal describes gastroscopy as the definitive diagnostic method and identifies omeprazole as the mainstay of acid suppression, while noting that treatment is usually more successful for ESGD than for EGGD. The same review says glandular disease may require longer treatment, combination therapy such as sucralfate, or alternatives such as misoprostol. (sciencedirect.com)

The deeper background is that acid suppression helps create conditions for healing, but it doesn’t solve the underlying drivers on its own. A 2021 open-access review on ESGD management states that treatment should be paired with management changes to reduce recurrence. It also notes that ranitidine and other H2-receptor antagonists are generally less effective than omeprazole in adult horses, and that there is no licensed equine H2-receptor antagonist product at present. The same review points to practical risk factors that clinicians already recognize, including high-starch feeding patterns, limited forage, exercise intensity, and stress. (pmc.ncbi.nlm.nih.gov)

The recurrence problem is where the latest research adds useful perspective. In a blinded, randomized, placebo-controlled clinical trial published online ahead of print in Equine Veterinary Journal on December 30, 2025, investigators evaluated a commercially available nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment in 30 horses with recent ESGD and EGGD. The product did not significantly outperform placebo in preventing recurrence by gastroscopy. Only five horses remained ulcer-free by the end of the study, although the nutraceutical group showed lower salivary ADA and higher bicarbonate concentrations, findings the authors said could suggest improved gastric mucosal health but still require validation. (pubmed.ncbi.nlm.nih.gov)

That result fits with the broader supplement literature, which is mixed at best. The ESGD review found some adjunct products have shown signals of benefit in specific settings, but others, including aloe vera and some herbal blends, have not matched omeprazole or placebo expectations. It also highlights evidence that dietary modification after omeprazole discontinuation can influence whether ulcers recur, with high-fiber, low-starch feeding associated with better maintenance of improvement. (pmc.ncbi.nlm.nih.gov)

Expert commentary in The Horse has also emphasized the diagnostic piece. In a 2024 article, Frank Andrews said gastroscopy remains the only definitive way to diagnose gastric ulcers, while behavior changes and other clinical signs can be nonspecific. That’s especially relevant for practitioners deciding when to scope, when to start empiric treatment, and when to re-scope to document healing, particularly in horses with persistent performance or behavioral complaints. (thehorse.com)

Why it matters: For veterinary professionals, this is a reminder that equine gastric disease management is increasingly about precision, not just acid suppression. ESGD and EGGD should not be treated as interchangeable. Omeprazole still anchors therapy, but recurrence after discontinuation is common, evidence for tapering remains limited, and nutraceuticals have yet to show reliable prevention of relapse on endoscopic outcomes. In practice, that means the strongest care plans are likely to combine lesion-specific diagnosis, realistic expectations for glandular disease, follow-up gastroscopy when feasible, and explicit counseling for pet parents and trainers on forage access, meal composition, exercise scheduling, transport stress, and other management factors that can undo pharmacologic gains. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase to watch is whether better recurrence-prevention strategies emerge for EGGD and mixed-disease cases, including stronger trials of adjunctive therapies, more validated biomarkers, and clearer protocols for maintaining remission after omeprazole. (pubmed.ncbi.nlm.nih.gov)